Eliem Therapeut filed with the US Securities and Exchange Commission to raise up to $80 million, as reported NASDAQ.
Pricing terms were not disclosed.
The company's two lead candidates are ETX-810, which is being developed for diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy, and ETX-155, which is being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures.
ETX-810 is being evaluated in two Phase IIa trials that are expected to report topline data next year, and the company plans to initiate two Phase IIa trials for ETX-155 in patients with MDD and PMD, which are expected to report topline data in 2023.
To read more NewsPoints articles, click here.